source
- Novo Nordisk looks to bolt-on acquisitions as pipeline setbacks mountNovo Nordisk CEO Maziar Mike Doustdar said on a media call that the pharma industry is tough for those who dislike setbacks and failure. He highlighted recent disappointments in the company's pipe…
- Attovia Therapeutics raises $289 million in IPO, adding third I&I drug to market debutAttovia Therapeutics, a biotech focused on immunology and inflammation, completed an initial public offering that raised about $289 million. The funds will support the development of three I&I dru…